How many insider trades does FilingIQ track for PCVX?

FilingIQ tracks 865 Form 4 insider transactions for PCVX (Vaxcyte, Inc.), covering filings from Jun 16, 2020 onwards. 42 of those were filed in the last 90 days.

Are PCVX insiders net buyers or net sellers?

Across the full Form 4 history for PCVX, 4 transactions (0%) were open-market purchases and 514 (59%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does PCVX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is PCVX in?

Vaxcyte, Inc. (PCVX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.35B.

PCVX insider trading

NasdaqGS Healthcare

Vaxcyte, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

865

Last 90 days

Buys / sells

0% / 59%

Market cap

$8.35B

About Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Company website: vaxcyte.com

PCVX insider activity at a glance

FilingIQ has scored 865 insider transactions for PCVX since Jun 16, 2020. The most recent filing in our index is dated May 1, 2026.

Across the full history, 4 open-market purchases and 514 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on PCVX insider trades is 61.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live PCVX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding PCVX

Frazier Life Sciences Management, L.P.

$67.01M · 4.2% of AUM

Frequently asked

How many insider trades does FilingIQ track for PCVX?: FilingIQ tracks 865 Form 4 insider transactions for PCVX (Vaxcyte, Inc.), covering filings from Jun 16, 2020 onwards. 42 of those were filed in the last 90 days.
Are PCVX insiders net buyers or net sellers?: Across the full Form 4 history for PCVX, 4 transactions (0%) were open-market purchases and 514 (59%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does PCVX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is PCVX in?: Vaxcyte, Inc. (PCVX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.35B.

Methodology & sources

Every PCVX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.